<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869684</url>
  </required_header>
  <id_info>
    <org_study_id>MT-0814/2-01</org_study_id>
    <nct_id>NCT03869684</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration</brief_title>
  <official_title>A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Senju Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Senju Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related macular degeneration (AMD) is the leading cause of blindness among adults in
      North America. The current standard of care for patients with exudative (&quot;wet&quot;) AMD is
      anti-vasoendothelial growth factor (anti-VEGF) therapy) which must be administered by an
      injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of
      patients with exudative AMD, and could offer an alternative, safer and less burdensome
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study terminated for safety reasons
  </why_stopped>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Actual">April 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best-corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from Baseline in BCVA measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Central Subfield Thickness (CSFT)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from Baseline in CSFT, measured by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>MT-0814 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-0814 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-0814 plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-0814</intervention_name>
    <description>Randomly assigned dose</description>
    <arm_group_label>MT-0814 High dose</arm_group_label>
    <arm_group_label>MT-0814 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo manufactured to mimic MT-0814</description>
    <arm_group_label>MT-0814 Low dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must agree to sign informed consent form, and to comply with protocol requirements,
             including study visits.

          -  Must have clear optic media in the study eye that is capable of producing high-quality
             fundus images.

        Exclusion Criteria:

          -  Has active CNV due to causes other than AMD in the study eye.

          -  Has retinal vascular disease or retinal degeneration other than AMD in the study eye.

          -  Has had intraocular surgery, cataract surgery or LASIK surgery on the study eye within
             90 days prior to the study.

          -  Has had yttrium aluminum garnet (YAG) laser capsulotomy on the study eye within 30
             days prior to the study.

          -  Has active inflammation, infection, or other severe ocular disease in either eye.

          -  Has aphakia in the study eye.

          -  Has uncontrolled glaucoma or a history of previous glaucoma filter surgery in either
             eye.

          -  Is a contact lens wearer and is unable to discontinue their use in both eyes for the
             duration of the study.

          -  Has a serious allergy to, or experienced a prior significant adverse reaction to
             fluorescein angiography (FA) or indocyanine green angiography (ICGA).

          -  Has participated in any other clinical trial and/or has taken any investigational drug
             or product within 90 days prior to the study.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senju Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exudative</keyword>
  <keyword>Wet</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Age related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

